Role of Antiplatelets and Anticoagulation Therapies in Pregnancy
Author Information
Author(s): Zachariah Krista A., Yuan Su, DeSancho Maria T., Landres Inna V., Singh Harsimran S.
Primary Institution: NewYork-Presbyterian Hospital-Weill Cornell Medicine
Hypothesis
The study aims to provide a narrative review of the established and emerging indications of antiplatelets and anticoagulants during pregnancy.
Conclusion
Antiplatelet and anticoagulation therapies are crucial in managing thrombotic risks during pregnancy, but their use requires careful consideration of maternal and fetal risks.
Supporting Evidence
- Pregnancy is a hypercoagulable state, increasing the risk of thrombotic complications.
- Current guidelines support the selective use of aspirin, heparin, and warfarin in pregnant women.
- Low-dose aspirin can reduce the risk of preeclampsia in high-risk pregnant women.
Takeaway
Pregnant women need special care when using blood thinners to prevent clots because it can be tricky to balance the benefits and risks for both mom and baby.
Methodology
This is a narrative review discussing the indications, timing, and risks associated with antiplatelet and anticoagulant therapies in pregnancy.
Limitations
The review lacks large randomized controlled trials specifically studying fetal safety in the context of pregnancy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website